Skip to content

Labetalol for chronic hypertension

Methyldopa versus Labetalol or no medication for treatment of chronic hypertension during pregnancy: a double blinded randomized clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201707002463243
Enrollment
480
Registered
2017-07-24
Start date
2017-08-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory System Pregnancy and Childbirth Treatment of chronic hypertension

Interventions

Sponsors

Faculty of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Pregnant women diagnosed with mild to moderate chronic hypertension, with systolic blood pressure of 140¿159 mmHg or diastolic blood pressure of 90¿109 mmHg, at the beginning of pregnancy were included in the study.

Exclusion criteria

Exclusion criteria: Women with multiple pregnancies, women with proteinuria at less than 20 weeks¿ gestation, women having other associated medical disorders as diabetes mellitus, bronchial asthma & epilepsy and pregnancies complicated by fetal malformations were excluded from the study.

Design outcomes

Primary

MeasureTime frame
maternal outcome;Fetal-neonatal outcome

Countries

Egypt

Contacts

Public ContactMohamed Rezk

Assistant Professor of Obstetrics and Gynecology

m_rezk9207@yahoo.com00201006237186

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026